Mapoli

Sitagliptin, the active ingredient in Mapoli, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It helps lower blood glucose in adults with type 2 diabetes mellitus.

GNH USA supplies Mapoli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mapoli (sitagliptin) is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance.

Type 2 diabetes mellitus: improves glycemic control as an adjunct to diet and exercise. Type 2 diabetes mellitus (monotherapy): provides glucose lowering when metformin is not tolerated. Type 2 diabetes mellitus (combination therapy): enhances overall HbA1c reduction when used with other oral antidiabetics.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Dizziness: occasional light‑headed sensation. - Joint pain: arthralgia without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: elevated liver enzymes or jaundice. - Acute kidney injury: reduced renal function in susceptible patients. - Hypersensitivity pneumonitis: rare lung inflammation.

Before initiating therapy, consider the following precautions: - Renal function: assess creatinine clearance and adjust dose if necessary. - History of pancreatitis: monitor for recurrent abdominal pain. - Hypersensitivity: discontinue if rash, pruritus, or angioedema develop. - Cardiovascular risk: use with caution in patients with heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines. Review the following:

Major Interactions (Avoid): - Insulin: combined use can increase risk of hypoglycemia. - Sulfonylureas (e.g., glipizide): may potentiate hypoglycemic episodes. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin exposure, lowering efficacy. - Diuretics: can affect glucose control, requiring monitoring. - ACE inhibitors: may enhance antihypertensive effect, watch blood pressure.